Pharma BD Deal Intelligence

Rosemont Pharmaceuticals Holdings, Inc. / Aytu BioPharma, Inc.

2026 · Acquisition/Merger · $56M · Pending

Aytu BioPharma entered an Agreement and Plan of Merger with Rosemont Pharmaceuticals Holdings and its wholly owned subsidiary RoseApollo Merger Sub under which Rosemont will acquire Aytu for $2.70 per share in cash, representing total consideration of approximately $56 million on a fully diluted basis and a 41.1% premium to Aytu's 30-day volume weighted average share price. The transaction is structured as a tender offer followed by a second-step merger at the same price, conditioned on tender of a majority of outstanding shares and the exercise or termination of certain outstanding warrants. Aytu's board unanimously approved the transaction, and executive officers, directors and stockholders affiliated with Nantahala Capital Management and Stonepine Capital Management signed tender and support agreements. Rosemont's stated rationale is accelerating its US expansion with an established ADHD portfolio, an emerging major depressive disorder asset and a US commercial platform.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →